Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

被引：59

作者：

Brunetti, Oronzo ^{[1
]}

Gnoni, Antonio ^{[2
]}

Licchetta, Antonella ^{[2
]}

Longo, Vito ^{[3
]}

Calabrese, Angela ^{[4
]}

Argentiero, Antonella ^{[1
]}

Delcuratolo, Sabina ^{[5
]}

Solimando, Antonio Giovanni ^{[1
,6
]}

Casadei-Gardini, Andrea ^{[7
,8
]}

Silvestris, Nicola ^{[1
,9
]}

机构：

[1] Ist Tumori Giovanni Paolo II, Med Oncol Unit, IRCCS, Natl Canc Res Ctr, I-70124 Bari, Italy

[2] S Cuore di Gesu Hosp, Med Oncol Unit, I-73014 Gallipoli, Italy

[3] Ist Tumori Giovanni Paolo II, Med Thorac Oncol Unit, IRCCS, I-70124 Bari, Italy

[4] Ist Tumori Giovanni Paolo II, Radiol Unit, IRCCS, Natl Canc Res Ctr, I-70124 Bari, Italy

[5] Ist Tumori Giovanni Paolo II, IRCCS, Natl Canc Res Ctr, Sci Direct, I-70124 Bari, Italy

[6] Univ Bari, Dept Biomed Sci & Human Oncol, Sect Internal Med G Baccelli, Med Sch, I-70124 Bari, Italy

[7] IRCCS, Dept Med Oncol, Ist Sci Romagnolo Studio & Cura Tumori IRST, I-47014 Meldola, Italy

[8] Univ Hosp Modena, Dept Oncol & Haematol, I-41125 Modena, Italy

[9] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy

来源：

MEDICINA-LITHUANIA | 2019年 / 55卷 / 10期

关键词：

Sorafenib; hepatocellular carcinoma; prognostic factors; predictive factors; ADVANCED HEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LYMPHOCYTE RATIO; GROWTH-FACTOR; SURVIVAL; THERAPY; MICRORNAS; METFORMIN; EFFICACY; CELLS;

D O I：

10.3390/medicina55100707

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.

引用

页数：16

共 74 条

[1] A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
Abou-Alfa, Ghassan K.
Miksad, Rebecca A.
Tejani, Mohamedtaki A.
Williamson, Stephen
Gutierrez, Martin E.
Olowokure, Olugbenga O.
Sharma, Manish R.
El Dika, Imane
Sherman, Matthew L.
Pandya, Shuchi S.
[J]. ONCOLOGIST, 2019, 24 (02) : 161 - +
[2] FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Arao, Tokuzo
Ueshima, Kazuomi
Matsumoto, Kazuko
Nagai, Tomoyuki
Kimura, Hideharu
Hagiwara, Satoru
Sakurai, Toshiharu
Haji, Seiji
Kanazawa, Akishige
Hidaka, Hisashi
Iso, Yukihiro
Kubota, Keiichi
Shimada, Mitsuo
Utsunomiya, Tohru
Hirooka, Masashi
Hiasa, Yoichi
Toyoki, Yoshikazu
Hakamada, Kenichi
Yasui, Kohichiroh
Kumada, Takashi
Toyoda, Hidenori
Sato, Shuichi
Hisai, Hiroyuki
Kuzuya, Teiji
Tsuchiya, Kaoru
Izumi, Namiki
Arii, Shigeki
Nishio, Kazuto
Kudo, Masatoshi
[J]. HEPATOLOGY, 2013, 57 (04) : 1407 - 1415
[3] Immunotherapy for colorectal cancer: where are we heading?
Basile, Debora
Garattini, Silvio Ken
Bonotto, Marta
Ongaro, Elena
Casagrande, Mariaelena
Cattaneo, Monica
Fanotto, Valentina
De Carlo, Elisa
Loupakis, Fotios
Urbano, Federica
Negri, Francesca V.
Pella, Nicoletta
Russano, Marco
Brunetti, Oronzo
Scartozzi, Mario
Santini, Daniele
Silvestris, Nicola
Gardini, Andrea Casadei
Puzzoni, Marco
Calvetti, Lorenzo
Cardarelli, Nadia
Aprile, Giuseppe
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 709 - 721
[4] Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Bruix, Jordi
Cheng, Ann-Lii
Meinhardt, Gerold
Nakajima, Keiko
De Sanctis, Yoriko
Llovet, Josep
[J]. JOURNAL OF HEPATOLOGY, 2017, 67 (05) : 999 - 1008
[5] Micro-RNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti, Oronzo
Russo, Antonio
Scarpa, Aldo
Santini, Daniele
Reni, Michele
Bittoni, Alessandro
Azzariti, Amalia
Aprile, Giuseppe
Delcuratolo, Sabina
Signorile, Michele
Gnoni, Antonio
Palermo, Loredana
Lorusso, Vito
Cascinu, Stefano
Silvestris, Nicola
[J]. ONCOTARGET, 2015, 6 (27) : 23323 - 23341
[6] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Cainap, Calin
Qin, Shukui
Huang, Wen-Tsung
Chung, Ik Joo
Pan, Hongming
Cheng, Ying
Kudo, Masatoshi
Kang, Yoon-Koo
Chen, Pei-Jer
Toh, Han-Chong
Gorbunova, Vera
Eskens, Ferry A. L. M.
Qian, Jiang
McKee, Mark D.
Ricker, Justin L.
Carlson, Dawn M.
El-Nowiem, Saied
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77
[7] Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy
Chen, Chuan
Wang, Ge
[J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (15) : 1964 - 1970
[8] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, Ann-Lii
Kang, Yoon-Koo
Chen, Zhendong
Tsao, Chao-Jung
Qin, Shukui
Kim, Jun Suk
Luo, Rongcheng
Feng, Jifeng
Ye, Shenglong
Yang, Tsai-Sheng
Xu, Jianming
Sun, Yan
Liang, Houjie
Liu, Jiwei
Wang, Jiejun
Tak, Won Young
Pan, Hongming
Burock, Karin
Zou, Jessie
Voliotis, Dimitris
Guan, Zhongzhen
[J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
[9] Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
Di Costanzo, Giovan Giuseppe
Gardini, Andrea Casadei
Marisi, Giorgia
Foschi, Francesco Giuseppe
Scartozzi, Mario
Granata, Rocco
Faloppi, Luca
Cascinu, Stefano
Silvestris, Nicola
Brunetti, Oronzo
Palmieri, Vincenzo Ostilio
Ercolani, Giorgio
Tortora, Raffaella
[J]. TARGETED ONCOLOGY, 2017, 12 (06) : 795 - 803
[10] The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence
El-Serag, HB
Hampel, H
Javadi, F
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) : 369 - 380

← 1 2 3 4 5 6 7 8 →